$40.10
+0.97 (+2.48%)
Open$40.04
Previous Close$39.13
Day High$40.60
Day Low$38.97
52W High$43.57
52W Low$28.95
Volume—
Avg Volume663.1K
Market Cap2.05B
P/E Ratio95.42
EPS$0.36
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+8.7% upside
Current
$40.10
$40.10
Target
$43.60
$43.60
$27.22
$43.60 avg
$49.94
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 283.46M | 238.42M | 156.14M |
| Net Income | 16.95M | 12.83M | 35.53M |
| Profit Margin | 6.0% | 5.7% | 22.8% |
| EBITDA | 23.18M | 18.52M | 44.60M |
| Free Cash Flow | — | — | 32.60M |
| Rev Growth | +18.9% | +18.9% | +24.7% |
| Debt/Equity | 0.01 | 0.01 | 0.62 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.93 | +0.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $352.99 | +1.72% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.88 | +0.66% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $478.81 | +2.22% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $626.31 | +1.34% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $300.33 | +4.22% | 64.3 | 37.13B |